Want to join the conversation?
Drugs major $PFE said the U.S. FDA accepted for filing and granted Priority Review for a supplemental new drug application (sNDA) for breast cancer medication, IBRANCE (palbociclib). If $PFE's sNDA is approved, the updated IBRANCE label would constitute results from two metastatic breast cancer trials, PALOMA-1 and PALOMA-3.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?